Back to top
more

Galapagos (GLPG)

(Delayed Data from NSDQ)

$31.67 USD

31.67
240,238

+0.17 (0.54%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $31.67 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (146 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Galapagos (GLPG) Looks Good: Stock Adds 6.2% in Session

by Zacks Equity Research

Galapagos (GLPG) was a big mover last session, as the company saw its shares rise over 6% on the day.

    Zacks Equity Research

    Galapagos-Gilead Begin Phase II Study on Uveitis Candidate

    by Zacks Equity Research

    Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.

      Zacks Equity Research

      Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe

      by Zacks Equity Research

      Illumina, Inc. (ILMN) recently announced the launch of a solution pertaining to its noninvasive prenatal testing (NIPT) range in Europe.

        Zacks Equity Research

        Amedisys (AMED) Poised on Strong Home Health, Risks Remain

        by Zacks Equity Research

        On Apr 04, we issued an updated research report on renowned home health and hospice services provider, Amedisys Inc. (AMED).

          Zacks Equity Research

          Galapagos Initiates 3 Phase II Studies for Filgotinib

          by Zacks Equity Research

          Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.

            Zacks Equity Research

            QIAGEN Releases Favorable GeneReader Results, Expands in NGS

            by Zacks Equity Research

            QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.

              Zacks Equity Research

              The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial

              by Zacks Equity Research

              The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial

                Zacks Equity Research

                Can The Uptrend Continue for Galapagos (GLPG)?

                by Zacks Equity Research

                Investors certainly have to be happy with Galapagos NV (GLPG) and its short term performance

                  Zacks Equity Research

                  BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session

                  by Zacks Equity Research

                  BioTime, Inc. (BTX) was above 7% in the last trading session.

                    Zacks Equity Research

                    Why Galapagos (GLPG) Could Be Positioned for a Surge?

                    by Zacks Equity Research

                    Galapagos NV (GLPG) is a Medial-Biomedical and Genetics company that could be an interesting play for investors.